Moderna (MRNA +5.38%) soared onto the scene in early pandemic days with its messenger RNA technology and delivered a coronavirus vaccine in a matter of months. As the vaccine brought in blockbuster ...
・Moderna shares soared a record 177% after its personalized mRNA cancer vaccine, developed with Merck, succeeded in a Phase 3 melanoma trial. ・Wall Street called the result a major scientific ...
Merck's personalized cancer vaccine worked in a Phase 3 melanoma trial, adding $43 billion in value. Here is why it matters beyond skin cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results